The DOI matches its Crossref record.
MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression
Abstract
Breast cancer is the worldwide leading cause of cancer mortality in women. The majority of deaths from breast cancer arise from metastasis of local tumors. Cancer cells support their rapid proliferation by diverting metabolites into anabolic pathways, but during cancer metastasis, the proliferative program of invasive cancer cells is suspended for a migratory phenotype. In this study, we demonstrated that both mature forms of miRNA-485, miR-485-3p and miR-485-5p were involved in regulating mitochondrial respiration, cell migration and cell invasion in breast cancer cells by directly targeting and inhibiting the expression of PGC-1 α. Specifically, the expression levels of both miR-485-3p and miR-485-5p were decreased in breast cancer tissues. Overexpression of miR-485-3p and miR-485-5p suppressed mitochondrial respiration and potential for cell migration and invasion in vitro, and also inhibited spontaneous metastasis of breast cancer cells in vivo. The suppression of mitochondrial respiration and cell invasion could be partially relieved by restoration of PGC-1 α expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PGC-1α, a transcriptional coactivator regulating mitochondrial biogenesis and oxidative stress responses and considered a putative target of miR-485-3p, has been shown in previous cancer studies to directly bind miR-485-3p via its 3′-UTR [24,26].”
From Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis (2026) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 23
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90. · DOI
- Scully OJ, Bay BH, Yip G, Yu Y . Breast cancer metastasis. Cancer Genomics Proteomics 2012; 9: 311–320.
- Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–1033. · DOI · Paper page
- Warburg O . On the origin of cancer cells. Science 1956; 123: 309–314. · DOI · Paper page
- Locasale JW, Cantley LC . Metabolic flux and the regulation of mammalian cell growth. Cell Metab 2011; 14: 443–451. · DOI · Paper page
- LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 2014; 16: 1001–1015.
- Bertoli G, Cava C, Castiglioni I . MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 2015; 5: 1122–1143. · DOI
- Winter J, Jung S, Keller S, Gregory RI, Diederichs S . Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228–234. · DOI
- Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857–866. · DOI
- Liu YN, Yin J, Barrett B, Sheppard-Tillman H, Li D, Casey OM et al. Loss of androgen-regulated microRNA 1 activates SRC and promotes prostate cancer bone metastasis. Mol Cell Biol 2015; 35: 1940–1951. · DOI
- Zhang Q, Tang Q, Qin D, Yu L, Huang R, Lv G et al. Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis. Mol Cell Biol 2015; 35: 988–1000. · DOI
- Li X, Gong X, Chen J, Zhang J, Sun J, Guo M . miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2. Biochem Biophys Res Commun 2015; 460: 670–677. · DOI
- Labbaye C, Testa U . The emerging role of MIR-146 A in the control of hematopoiesis, immune function and cancer. J Hematol Oncol 2012; 5: 13. · DOI · Paper page
- Anaya-Ruiz M, Bandala C, Perez-Santos JL . miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cells. Asian Pac J Cancer Prev 2013; 14: 3757–3760. · DOI
- Ambros V . microRNAs: tiny regulators with great potential. Cell 2001; 107: 823–826. · DOI
- Shao D, Liu Y, Liu X, Zhu L, Cui Y, Cui A et al. PGC-1 beta-regulated mitochondrial biogenesis and function in myotubes is mediated by NRF-1 and ERR alpha. Mitochondrion 2010; 10: 516–527. · DOI
- Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y et al. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun 2013; 433: 207–212. · DOI
- Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X et al. miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis 2014; 35: 469–478. · DOI
- Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST et al. Identification of microRNAs as potential prognostic markers in ependymoma. PloS One 2011; 6: e25114. · DOI
- Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 2010; 57: 734–743. · DOI
- Chen CF, He X, Arslan AD, Mo YY, Reinhold WC, Pommier Y et al. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIalpha and drug responsiveness. Mol Pharmacol 2011; 79: 735–741. · DOI
- He N, Zheng H, Li P, Zhao Y, Zhang W, Song F et al. miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk. PloS One 2014; 9: e102093. · DOI
- Lieber D . Generation of a stable cell line for constitutive miRNA expression. Methods Mol Biol 2013; 1064: 183–200. · DOI
Cited by
Sorted by citations
Fracassi, A., Marcatti, M., Zolochevska, O., Tabor, N., Woltjer, R., Moreno, S., & Taglialatela, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.0295-20.2020 · Cited by 81
Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis
Ryu, I. S., Ha, D.-I., Jung, Y.-J., Lee, H. J., Kim, I., Lim, Y. N., Min, H. S., Kim, S. H., Yoon, I., Cho, H.-J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020615 · Cited by 2
Metadata
- Authors
- Lou, C., Xiao, M., Cheng, S., Lu, X., Jia, S., Ren, Y., & Li, Z.
- Venue
- Cell Death & Disease
- Published
- 2016-03-24
- Volume
- 7
- Issue
- 3
- Pages
- e2159-e2159
- ISSN
- 2041-4889
- PMC
- PMC4823935
- Cited by
- 137
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
